Enhance your nephrology practice with CME and tools focused on kidney medicine.
Call to Action: Utilizing Avacopan to Improve AAV Care
Stephen McAdoo, MD
Curbside Consult: Optimizing IgAN Management
Khalil El Karoui, MD
Federico Alberici, MD, PhD
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD, FASN
Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
Jay Reddy, MD, FASN
Carlos Narváez Mejía, MD
Understanding the Recent Advances in IgAN
Jürgen Floege, MD
Jonathan Barratt, PhD
I Just Need to Sleep! Improving Itch in Patients With CKD-aP
Kieran McCafferty, MD
Prof. Dr. Jörg Latus
Almost Like Being There: Updates in IgA Nephropathy From Kidney Week
Howard Trachtman, MD, FASN
Hiddo L. Heerspink, PhD
Why We Should Be PRO Patients With CKD-Associated Pruritus
Lucio Manenti, MD, PhD
Jeanette Finderup, PhD, MHR, RN
Sebastian Koball, MD
Call to Action: Elevating CKD-aP Care
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Hyperkalemia in CKD and HFrEF…What Am I Missing?
George L. Bakris, MD, FAHA, FASN
David Bushinsky, MD
Lars Lund, MD
C5a Receptor Inhibition With Avacopan: A Novel Treatment Approach for ANCA-Associated Vasculitis
A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Patrick Rossignol, MD, PhD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Loreto Gesualdo, MD, FERA
Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
Getting to the Root of CKD-Associated Pruritus: Questions From the Field
Joel Topf, MD
James Burton, MD
Exploring Developments in IgAN and FSGS
Richard Lafayette, MD, FACP
PROTECT Study in IgAN: Topline Data
Jonathan Barratt, MD
The CKD Patient: Thinking Beyond the Numbers and Dialysis
David Jayne, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
Bernhard Hellmich, MD
Separating Fact from Fiction: The Realities of CKD-aP
Antoine Lanot, MD, PhD
Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
Mario Cozzolino, MD, PhD
Jan T. Kielstein, MD, FASN, FERA
Case-Based Management of AAV
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We’re glad to see you’re enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.